ClinicalTrials.gg
TerminatedNCT06182579Updated Sep 17, 2025

Phase I Study of RiMO-401 With Radiation in Advanced Tumors

A Phase 1 interventional study of RiMO-401 in Advanced Solid Tumor and Intratumoral Injection, sponsored by Coordination Pharmaceuticals, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Coordination Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
slow enrollment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a single arm study of RiMO-401 with radiation in patients with advanced tumors. A single escalation dose of RiMO-401 is intratumorally injected in a 3+3 study design to identify the recommended dose.

Read the detailed description

Primary Objectives:

  • To determine the tolerability of RiMO-401 with palliative radiation as assessed by CTCAEv5

Secondary Objectives:

  • To determine clinical response of RiMO-401 with palliative radiotherapy
  • To characterize adverse events of RiMO-401 in patients with advanced cancers
  • To characterize the pharmacokinetics of RiMO-401 with palliative radiation

The target population comprises patients with clinically accessible lesions that can be trated with palliative radiation.

02

Conditions studied

  • Advanced Solid Tumor
  • Intratumoral Injection
03

In context

Lead sponsor

Coordination Pharmaceuticals, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of advanced or cancer not amenable to curative therapy
  • Lesion that is amenable to palliative radiotherapy
  • Lesion that is technically feasible for intratumoral injection
  • Target tumor in region not in the field that was irradiated within the past six months
  • Patients with advanced or metastatic HNSCC must have progressed on or been intolerant to standard of care therapies including platinum-based chemotherapy and anti-PD(L)1 therapy, prior to study enrollment
  • Patient must have recovered from acute toxic effects (≤ grade 1) of previous cancer treatments prior to enrollment
  • Has , defined as at least 1 tumor that fulfills the criteria for a target lesion
  • score of 0-1
  • Have a of at least 12 weeks
  • Have adequate bone marrow reserve and adequate liver function
  • Both males and females and their partners of must agree to use adequate measures
  • Patients must sign a study-specific form prior to study entry
  • Age 18 years or older.

Exclusion criteria

Exclusion Criteria:

  • Patients with a histological diagnosis of lymphomas and/or leukemias
  • Patients with significant blood vessels (such as carotid artery encasement) or other major structures in the tumor region to be injected
  • Patients may not have received chemotherapy, targeted therapies, immunotherapies, biologic response modifiers and/or hormonal therapy within the last 14 days
  • Ongoing infection at or near the incident lesion
  • Major surgery over the target area (excluding placement of vascular access) \<21 days from beginning of the study drug or minor surgical procedures \<7 days
  • Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that would make the patient inappropriate for enrollment in this study
  • Has any mental or medical condition that prevents the patient from giving or participating in the trial
  • Pregnant and nursing women
  • Patients with a target lesion located in a previously irradiated field
  • Patients with a target lesion in the field that had complications from prior radiotherapy that are not amenable to repeat irradiation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    RiMO-401

    • Single intratumoral injection followed by radiation

    Drug: RiMO-401

Interventions

  • DrugRiMO-401

    • Single intratumoral injection of RiMO-401 followed by palliative radiotherapy

    Also known as: Radiation

06

What researchers measure

Primary outcomes

  1. Determination of Recommended Dose

    The dose limiting toxicities of RiMO-401 with palliative radiation, as assessed by CTCAEv5, will not be observed in 33% or more patients

    Time frame: 45 Days

Secondary outcomes

  1. Evaluation of Objective Response Rate (ORR)

    The Objective Response Rate (ORR) will be determined by imaging according to RECIST 1.1

    Time frame: 45 Days

  2. Evaluation of Safety and Tolerability

    Incidence and severity of clinical and laboratory adverse events will be assessed according to CTCAEv5

    Time frame: 45 Days

Other outcomes

  1. Evaluation of Maximum Plasma Concentration (Cmax)

    Plasma concentrations of RiMO-401 will be measured until 8 days after administration

    Time frame: 8 Days

  2. Evaluation of Area Under the Curve (AUC)

    Plasma concentrations of RiMO-401 will be measured until 8 days after administration

    Time frame: 8 Days

07

Study locations

1 site
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Jun 2025, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2023
First posted
Dec 27, 2023
StartActual
Feb 22, 2024
Primary completionActual
Jun 16, 2025
CompletionActual
Jun 16, 2025
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06182579
Lead sponsor
Coordination Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Dec 27, 2023
Start date
Feb 22, 2024
Primary completion
Jun 16, 2025
Completion
Jun 16, 2025
Last update
Sep 17, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion